- Home
- HMY vs BLCO Comparison
HMY vs BLCO Comparison
Compare HMY & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMY
- BLCO
- Stock Information
- Founded
- HMY 1950
- BLCO 1853
- Country
- HMY South Africa
- BLCO Canada
- Employees
- HMY N/A
- BLCO N/A
- Industry
- HMY Precious Metals
- BLCO Ophthalmic Goods
- Sector
- HMY Basic Materials
- BLCO Health Care
- Exchange
- HMY Nasdaq
- BLCO Nasdaq
- Market Cap
- HMY 5.4B
- BLCO 6.3B
- IPO Year
- HMY N/A
- BLCO 2022
- Fundamental
- Price
- HMY $10.21
- BLCO $17.17
- Analyst Decision
- HMY Sell
- BLCO Buy
- Analyst Count
- HMY 3
- BLCO 12
- Target Price
- HMY $6.60
- BLCO $20.73
- AVG Volume (30 Days)
- HMY 6.1M
- BLCO 396.1K
- Earning Date
- HMY 01-01-0001
- BLCO 02-19-2025
- Dividend Yield
- HMY 1.27%
- BLCO N/A
- EPS Growth
- HMY 75.55
- BLCO N/A
- EPS
- HMY 0.75
- BLCO N/A
- Revenue
- HMY $3,362,293,253.00
- BLCO $4,684,000,000.00
- Revenue This Year
- HMY $15.52
- BLCO $17.32
- Revenue Next Year
- HMY $5.36
- BLCO $5.98
- P/E Ratio
- HMY $13.64
- BLCO N/A
- Revenue Growth
- HMY 24.56
- BLCO 18.01
- 52 Week Low
- HMY $5.41
- BLCO $13.16
- 52 Week High
- HMY $12.29
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- HMY 70.73
- BLCO 35.11
- Support Level
- HMY $8.95
- BLCO $17.00
- Resistance Level
- HMY $9.40
- BLCO $17.57
- Average True Range (ATR)
- HMY 0.29
- BLCO 0.45
- MACD
- HMY 0.22
- BLCO -0.00
- Stochastic Oscillator
- HMY 92.74
- BLCO 22.80
About HMY Harmony Gold Mining Company Limited
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.